Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Next Previous
Trial Profile

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDENCE
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 01 Apr 2025 Results of pooled analysis from CANVAS Program and CREDENCE assessing cardiovascular, kidney and safety outcomes with canagliflozin in older adults, published in the Diabetes, Obesity and Metabolism.
  • 01 Sep 2024 Results of a secondary analysis assessing effect of canagliflozin on kidney and cardiovascular events and safety outcomes in individuals with type 2 diabetes and chronic kidney disease published in the Diabetes, Obesity and Metabolism
  • 01 Apr 2024 Results assessing the association of angiopoietin 2 and VEGF-A with cardiorenal outcomes and investigated the effect of canagliflozin on angiopoietin 2 and VEGF-A concentration, published in the Clinical Journal of The American Society of Nephrology: CJASN

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top